Ok, I'm out of the options game.
Well, never was in, just tried to figure it out. Clearly, it's not for my personality type: rectilinear science, merely adding and subtracting numbers, watching plotted data sets. Risk determinations at the most elemental level.
I'll hold my AVXL shares; will take profits in the distant future, after great appreciation. I'll stick to what I know best, cellular biology and associated topics.
(And yes, were I to create a webpage telling the details of neuron chemistry, it would for many [well, most] be as arcane and inscrutable as the options game would be for me.)
Therein is the cause, I believe, of the narrow and horizontal AVXL trading range. Very few retail or even institutional investors can fathom the world-changing technologies in Anavex's arsenal. To them, Anavex is but another doomed-to-fail pharmaceutical start-up, with some hokey early phase data that cannot playout well in a real giant placebo-controlled double blind trial. They are certain of this because of the multitude of similar Alzheimer's drug Phase 3 trial failures.
But those good folks couldn't tell the difference between the secondary and tertiary structures of a peptide or protein, and how those apply to normalized enzyme function. Without such knowledge (in orders of magnitude greater depth) the unique significance of Anavex 2-73 (and later Anavex 3-71) cannot be usefully comprehended.
The only thing that will change AVSL share prices will be news of a financial nature from the company. We await such.
